In Vivo Metabolite Formation and In Vitro Cytochrome P450-Mediated Metabolism of Vonoprazan in Horses
Metabolites · 18.08.2026 · 16 (8) · 584
DOI: 10.3390/metabo16080584 ↗Kurz gefasst
Fachartikel in der Zeitschrift Metabolites, online erschienen am 18.08.2026. Verfasst von Camilo J Morales und 3 weiteren Autor:innen. Beteiligte Einrichtung: K.L. Maddy Equine Analytical Chemistry Laboratory (Pharmacology Section), School of Veterinary Medicine, University of California, Davis, Davis, CA 9…. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Center for Equine Health.
Abstract (Originalsprache)
Background/Objectives: Vonoprazan is a potassium-competitive acid blocker with potential for the treatment of equine gastric ulcer syndrome. Vonoprazan metabolic pathways in horses have not been characterized. This study aimed to identify vonoprazan metabolites following oral administration and to determine the metabolic enzymes responsible for their metabolism using in vitro models.
Methods
Six healthy adult Thoroughbred horses received vonoprazan (0.5 and 1 mg/kg PO) in a randomized crossover design. Plasma concentrations of vonoprazan-N-oxide (M-I) and vonoprazan-nitrone (M-III) were quantified using a validated liquid chromatography-tandem mass spectrometry method, and a non-compartmental pharmacokinetic analysis was performed. In vitro metabolism was evaluated using equine liver microsomes (ELMs) and equine recombinant CYP450 (eq-rCYP) enzymes. Enzyme kinetics were characterized using nonlinear regression modeling.
Results
Both metabolites were detected in plasma after oral administration. Systemic exposure to M-I was markedly greater than M-III at both doses. At 1 mg/kg, mean ± SD Cmax values were 39.2 ± 28.3 ng/mL for M-I and 1.67 ± 1.66 ng/mL for M-III. AUC0–∞ increased dose-proportionally for both metabolites. In ELMs, M-I formation followed substrate inhibition kinetics, whereas M-III formation followed Michaelis–Menten kinetics. Among recombinant enzymes, CYP2D50 and CYP3A94 were the primary contributors to metabolite formation, exhibiting metabolite-specific kinetic profiles.
Conclusions
These findings demonstrate that vonoprazan undergoes hepatic oxidative metabolism in horses, with M-I as the predominant circulating metabolite. Equine recombinants CYP2D50 and CYP3A94 appear to play central roles in equine vonoprazan metabolism, providing foundation for future evaluation of drug–drug interaction potential and clinical use in this species.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- K.L. Maddy Equine Analytical Chemistry Laboratory (Pharmacology Section), School of Veterinary Medicine, University of California, Davis, Davis, CA 95616, USA.
- Department of Molecular Biosciences, School of Veterinary Medicine, University of California, Davis, Davis, CA 95616, USA.
ORCID-Profile: Camilo J Morales
Förderung
- Center for Equine Health
Zitieren
APA
Morales, C. J., Mckemie, D. S., Neupane, J. B., & Knych, H. K. (2026). In Vivo Metabolite Formation and In Vitro Cytochrome P450-Mediated Metabolism of Vonoprazan in Horses. Metabolites, 16(8), 584. https://doi.org/10.3390/metabo16080584
Vancouver
Morales CJ, Mckemie DS, Neupane JB, Knych HK. In Vivo Metabolite Formation and In Vitro Cytochrome P450-Mediated Metabolism of Vonoprazan in Horses. Metabolites. 2026;16(8):584. doi:10.3390/metabo16080584
BibTeX
@article{Morales2026,
author = {Morales, Camilo J and Mckemie, Daniel S and Neupane, Jayanti Bhandari and Knych, Heather K},
title = {In Vivo Metabolite Formation and In Vitro Cytochrome P450-Mediated Metabolism of Vonoprazan in Horses},
journal = {Metabolites},
year = {2026},
volume = {16},
number = {8},
pages = {584},
doi = {10.3390/metabo16080584}
}
EUVIMED